North Berkeley Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-5,500
Closed -$202K 79
2026
Q1
$202K Buy
+5,500
New +$261K 0.11% 72
2025
Q3
Sell
-4,740
Closed -$327K 67
2025
Q2
$327K Sell
4,740
-1,632
-26% -$111K 0.3% 49
2025
Q1
$442K Sell
6,372
-2,128
-25% -$176K 0.46% 37
2024
Q4
$731K Buy
+8,500
New +$919K 0.74% 23

Other funds holding NVO

North Berkeley Wealth Management's NVO Position: Q2 2026 in Review

North Berkeley Wealth Management sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 5,500 shares — an estimated $202K sold.

North Berkeley Wealth Management first reported a position in NVO in Q4 2024 and held it in 4 quarters. The position peaked at $731K in Q4 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • North Berkeley Wealth Management reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • North Berkeley Wealth Management sold 5,500 Novo Nordisk shares in Q2 2026, an estimated $202K.
  • North Berkeley Wealth Management first reported a position in Novo Nordisk in Q4 2024 and held it in 4 quarters.
  • North Berkeley Wealth Management's Novo Nordisk position peaked at $731K in Q4 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on North Berkeley Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.